Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 12 studies | 22% ± 5% | |
gamma-delta T cell | 5 studies | 20% ± 5% | |
natural killer cell | 4 studies | 22% ± 5% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 4 studies | 22% ± 11% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 26% ± 9% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 30% ± 8% | |
mature NK T cell | 3 studies | 19% ± 2% |
Insufficient scRNA-seq data for expression of CRTAM at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 148.02 | 578 / 578 | 67% | 2.18 | 777 / 1155 |
breast | 55% | 21.02 | 253 / 459 | 60% | 1.94 | 671 / 1118 |
spleen | 100% | 297.52 | 241 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 16.89 | 28 / 29 |
thymus | 52% | 27.01 | 338 / 653 | 44% | 1.81 | 264 / 605 |
bladder | 62% | 22.48 | 13 / 21 | 32% | 0.91 | 163 / 504 |
stomach | 59% | 17.18 | 211 / 359 | 35% | 1.03 | 99 / 286 |
uterus | 46% | 11.19 | 78 / 170 | 46% | 1.58 | 209 / 459 |
peripheral blood | 91% | 228.84 | 847 / 929 | 0% | 0 | 0 / 0 |
kidney | 30% | 10.08 | 27 / 89 | 59% | 2.45 | 529 / 901 |
prostate | 62% | 20.10 | 151 / 245 | 24% | 0.46 | 121 / 502 |
skin | 30% | 7.52 | 544 / 1809 | 54% | 2.93 | 254 / 472 |
tonsil | 0% | 0 | 0 / 0 | 80% | 4.23 | 36 / 45 |
intestine | 50% | 29.90 | 486 / 966 | 28% | 0.72 | 147 / 527 |
adipose | 71% | 32.80 | 860 / 1204 | 0% | 0 | 0 / 0 |
brain | 64% | 1927.11 | 1689 / 2642 | 7% | 0.22 | 50 / 705 |
liver | 54% | 14.54 | 121 / 226 | 17% | 0.53 | 69 / 406 |
pancreas | 14% | 3.23 | 45 / 328 | 54% | 1.37 | 97 / 178 |
ovary | 19% | 7.38 | 35 / 180 | 29% | 0.76 | 126 / 430 |
blood vessel | 44% | 16.70 | 590 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 20% | 4.98 | 296 / 1445 | 23% | 0.53 | 42 / 183 |
adrenal gland | 33% | 16.61 | 84 / 258 | 4% | 0.13 | 10 / 230 |
heart | 14% | 3.26 | 117 / 861 | 0% | 0 | 0 / 0 |
muscle | 13% | 3.95 | 108 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 9% | 0.38 | 7 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045580 | Biological process | regulation of T cell differentiation |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_2001185 | Biological process | regulation of CD8-positive, alpha-beta T cell activation |
GO_0001913 | Biological process | T cell mediated cytotoxicity |
GO_0001768 | Biological process | establishment of T cell polarity |
GO_0097021 | Biological process | lymphocyte migration into lymphoid organs |
GO_0046007 | Biological process | negative regulation of activated T cell proliferation |
GO_0008037 | Biological process | cell recognition |
GO_0050863 | Biological process | regulation of T cell activation |
GO_0051606 | Biological process | detection of stimulus |
GO_0002355 | Biological process | detection of tumor cell |
GO_0050798 | Biological process | activated T cell proliferation |
GO_0002860 | Biological process | positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_0001819 | Biological process | positive regulation of cytokine production |
GO_0007157 | Biological process | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules |
GO_0001772 | Cellular component | immunological synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0005102 | Molecular function | signaling receptor binding |
Gene name | CRTAM |
Protein name | Cytotoxic and regulatory T-cell molecule (Class-I MHC-restricted T-cell-associated molecule) (CD antigen CD355) |
Synonyms | |
Description | FUNCTION: Mediates heterophilic cell-cell adhesion which regulates the activation, differentiation and tissue retention of various T-cell subsets (By similarity). Interaction with CADM1 promotes natural killer (NK) cell cytotoxicity and IFNG/interferon-gamma secretion by CD8+ T-cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM1 in vivo . Regulates CD8+ T-cell proliferation in response to T-cell receptor (TCR) activation (By similarity). Appears to be dispensable for CD8+ T-cell-mediated cytotoxicity (By similarity). Interaction with SCRIB promotes the late phase of cellular polarization of a subset of CD4+ T-cells, which in turn regulates TCR-mediated proliferation and IFNG, IL17 and IL22 production (By similarity). By interacting with CADM1 on CD8+ dendritic cells, regulates the retention of activated CD8+ T-cells within the draining lymph node (By similarity). Required for the intestinal retention of intraepithelial CD4+ CD8+ T-cells and, to a lesser extent, intraepithelial and lamina propria CD8+ T-cells and CD4+ T-cells (By similarity). Interaction with CADM1 promotes the adhesion to gut-associated CD103+ dendritic cells, which may facilitate the expression of gut-homing and adhesion molecules on T-cells and the conversion of CD4+ T-cells into CD4+ CD8+ T-cells (By similarity). . |
Accessions | ENST00000533709.1 [O95727-2] O95727 ENST00000227348.9 [O95727-1] |